The global Human Microbiome Therapeutics Market is Expected to Reach a high CAGR of 30% during the forecast period (2022 – 2029).
The human body serves as a host to a networked community of microbiome that outnumbers the body’s cells. The microbiome comprises all of the genetic material within a microbiota that is equivalent to the entire collection of microorganisms in a specific niche, such as the human gut or oral cavity. The interaction between the human microbiome and the immune system affects several human metabolic functions and impacts well-being. The microbiome is a viable alternative for disease research, providing a more detailed analysis of the species present in the microbiome. The study of the human microbiome is done to determine the role of these microbes in human health and diseases caused as the microbes present may be pathogenic or beneficial.
The human microbiome market growth is driven by several factors, such as massive investment in microbiome research, an increase in government funding, and technological advancements.
The microbiome is attracting a lot of investment from the government as well as prominent private organizations. There are various companies and startups that are working in the field which accounts for a total of around 120. According to a report published by the Wall Street Journal, the investment in microbiome firms has increased from 2011 to 2015 by about 500%. The increase in investment and funding is due to the awareness of the uses and harms of the microbiome and how they affect the human body. Such discoveries can lead to breakthroughs in many human diseases treatments. For instance, uBiome, a company working in the microbiome segment, is developing genomic tests meant to identify and diagnose harmful microbes in the body. One of the applications of the microbiome is personalized medicine, Human Longevity Inc., is putting $220 million into the microbiome DNA to uncover disease-associated imbalances in microbial populations. This latter case is aimed at the development of personalized medicines for patients with different conditions.
The government of developed economies is also aware of the importance of the microbiome and thus has initiated many million-dollar projects for the research and development of the field. For instance, the Human Microbiome Project (HMP) by the National Institute of Health set the goal of identifying and characterizing the microorganisms which are found in association with both healthy and diseased humans and the National Microbiome Initiative, has accelerated research on the human microbiome are the two major products initiated by the U.S. government in the field of the human microbiome. The project was funded with $115 million by the U.S. government.
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/human-microbiome-therapeutics
- Targeted Gene
- Whole Genome
- Synthesis By
- Synthesis By Ligation
- Genetic Screening
- Drug Discovery
Some of the major key players in the market are BaseClear BV, Clinical Microbiomics AS, Locus Biosciences, Microbiome Insights Inc., Microbiome Therapeutics LLC, MR DNA, Second Genome, uBiome, Molzym GmbH, and Zymo Research Corp.
In the human microbiome market, the key players are adopting various growth strategies such as new product launches, partnerships, and collaborations with multiple research institutes and increasing research and development and high investment which are contributing to the growth of the human microbiome market globally.
In March 2019, BaseClear received the new ISO/IEC 17025 scope which now includes Next-Generation. The ISO/IEC 17025 accreditation is granted to laboratory tests that meet internationally validated quality requirements.
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions.